Global Subcutaneously Injected PD-L1 Antibody Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11243325

Publication Date:

November 8, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Manufacturing (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

PD-L1 antibody is a type of drug in tumor immunotherapy, which reduces immune suppression by binding to PD-L1 and blocking the binding between PD-1 and PD-L1, allowing T cells to exert anticancer effects. At present, PD-L1 antibodies on the market are generally administered intravenously, while subcutaneous injection can avoid various adverse reactions of intravenous infusion and improve patients' medical experience and quality of life.
The global Subcutaneously Injected PD-L1 Antibody market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淪ubcutaneously Injected PD-L1 Antibody Industry Forecast鈥� looks at past sales and reviews total world Subcutaneously Injected PD-L1 Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected Subcutaneously Injected PD-L1 Antibody sales for 2023 through 2029. With Subcutaneously Injected PD-L1 Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Subcutaneously Injected PD-L1 Antibody industry.
This Insight Report provides a comprehensive analysis of the global Subcutaneously Injected PD-L1 Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Subcutaneously Injected PD-L1 Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Subcutaneously Injected PD-L1 Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Subcutaneously Injected PD-L1 Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Subcutaneously Injected PD-L1 Antibody.
United States market for Subcutaneously Injected PD-L1 Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Subcutaneously Injected PD-L1 Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Subcutaneously Injected PD-L1 Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Subcutaneously Injected PD-L1 Antibody players cover Roche, Alphamab Oncology, Bristol Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Subcutaneously Injected PD-L1 Antibody market by product type, application, key players and key regions and countries.
Segmentation by Type:
Add Hyaluronidase
No Hyaluronidase
Segmentation by Application:
Rectal and Renal Cancer
Lung Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Add Hyaluronidase
No Hyaluronidase
Segmentation by Application:
Rectal and Renal Cancer
Lung Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Alphamab Oncology
Bristol Myers Squibb

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Subcutaneously Injected PD-L1 Antibody Market Size 2025-2030
2.1.2 Subcutaneously Injected PD-L1 Antibody Market Size CAGR by Region
2.2 Subcutaneously Injected PD-L1 Antibody Segment by Type
2.2.1 Add Hyaluronidase
2.2.2 No Hyaluronidase
2.3 Subcutaneously Injected PD-L1 Antibody Market Size by Type
2.3.1 Global Subcutaneously Injected PD-L1 Antibody Market Size Market Share by Type (2025-2030)
2.3.2 Global Subcutaneously Injected PD-L1 Antibody Market Size Growth Rate by Type (2025-2030)
2.4 Subcutaneously Injected PD-L1 Antibody Segment by Application
2.4.1 Rectal and Renal Cancer
2.4.2 Lung Cancer
2.4.3 Other
2.5 Subcutaneously Injected PD-L1 Antibody Market Size by Application (2025-2030)
2.5.1 Global Subcutaneously Injected PD-L1 Antibody Market Size Market Share by Application (2025-2030)
2.5.2 Global Subcutaneously Injected PD-L1 Antibody Market Size Growth Rate by Application (2025-2030)
3 Subcutaneously Injected PD-L1 Antibody Key Players
3.1 Date of Key Players Enter into Subcutaneously Injected PD-L1 Antibody
3.2 Key Players Subcutaneously Injected PD-L1 Antibody Product Offered
3.3 Key Players Subcutaneously Injected PD-L1 Antibody Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players Subcutaneously Injected PD-L1 Antibody Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 Subcutaneously Injected PD-L1 Antibody by Regions
4.1 Subcutaneously Injected PD-L1 Antibody Market Size by Regions (2025-2030)
4.2 United States Subcutaneously Injected PD-L1 Antibody Market Size Growth (2025-2030)
4.3 China Subcutaneously Injected PD-L1 Antibody Market Size Growth (2025-2030)
4.4 Europe Subcutaneously Injected PD-L1 Antibody Market Size Growth (2025-2030)
4.5 Rest of World Subcutaneously Injected PD-L1 Antibody Market Size Growth (2025-2030)
5 United States
5.1 United States Subcutaneously Injected PD-L1 Antibody Market Size by Type (2025-2030)
5.2 United States Subcutaneously Injected PD-L1 Antibody Market Size by Application (2025-2030)
6 Europe
6.1 Europe Subcutaneously Injected PD-L1 Antibody Market Size by Type (2025-2030)
6.2 Europe Subcutaneously Injected PD-L1 Antibody Market Size by Application (2025-2030)
7 China
7.1 China Subcutaneously Injected PD-L1 Antibody Market Size by Type (2025-2030)
7.2 China Subcutaneously Injected PD-L1 Antibody Market Size by Application (2025-2030)
8 Rest of World
8.1 Rest of World Subcutaneously Injected PD-L1 Antibody Market Size by Type (2025-2030)
8.2 Rest of World Subcutaneously Injected PD-L1 Antibody Market Size by Application (2025-2030)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Key Investors in Subcutaneously Injected PD-L1 Antibody
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 鈥︹€�
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Subcutaneously Injected PD-L1 Antibody Product Offered
11.1.3 Roche Subcutaneously Injected PD-L1 Antibody Market Size (2023 VS 2028)
11.1.4 Roche Main Business Overview
11.1.5 Roche News
11.2 Alphamab Oncology
11.2.1 Alphamab Oncology Company Details
11.2.2 Alphamab Oncology Subcutaneously Injected PD-L1 Antibody Product Offered
11.2.3 Alphamab Oncology Subcutaneously Injected PD-L1 Antibody Market Size (2023 VS 2028)
11.2.4 Alphamab Oncology Main Business Overview
11.2.5 Alphamab Oncology News
11.3 Bristol Myers Squibb
11.3.1 Bristol Myers Squibb Company Details
11.3.2 Bristol Myers Squibb Subcutaneously Injected PD-L1 Antibody Product Offered
11.3.3 Bristol Myers Squibb Subcutaneously Injected PD-L1 Antibody Market Size (2023 VS 2028)
11.3.4 Bristol Myers Squibb Main Business Overview
11.3.5 Bristol Myers Squibb News
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂